# Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

> **NCT00544700** · PHASE3 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 265 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **OTHER:** no maintenance

## Key facts

- **NCT ID:** NCT00544700
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11-26
- **Primary completion:** 2013-01-21
- **Final completion:** 2019-12-12
- **Target enrollment:** 265 (ACTUAL)
- **Why stopped:** Data collection is completed. As no changes in the endpoints were expected in the future, no further data is needed.
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544700, "Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00544700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*